Primary liver cancer is one of the most common malignant tumors in China, especially large liver cancer, which is known as the “king of cancer” because of its short survival period and tricky treatment. It is known as the “king of cancers”. 42% of new liver cancers occur in mainland China every year worldwide, and it is the second cause of death of tumors in China. Since the use of interventional treatment for liver cancer in the 1980s, it has quickly gained popularity among patients because of its characteristics of small trauma, fast recovery, good efficacy and relatively few complications, and clinical results over the past 20 years have shown that interventional treatment for liver cancer is significantly better than traditional treatment methods and has become the first choice for the treatment of middle and late stage liver cancer. Interventional treatment of liver cancer is a method to diagnose and treat liver cancer by inserting special puncture needles and catheters into the tumor area of liver under the guidance of imaging equipment (such as X-ray TV, CT, B-ultrasound). The catheter is then inserted super-selectively into the tumor-supplying artery and the tumor cells are “poisoned” by injecting highly concentrated chemotherapeutic drugs through the catheter. In this way, the source of blood supply to the tumor can be blocked and the anti-cancer drug can be injected into the tumor area in high concentration, and the drug can stay in the tumor for a longer time. Finally, the tumor blood supply artery is embolized with embolic material to “starve” the tumor to death. The postoperative wound is the same size as the wound after infusion and puncture. The principle of transvascular interventional therapy: The efficacy of interventional therapy for liver cancer is determined by the characteristics of blood supply to liver cancer. Normally, the liver is supplied with blood by the hepatic artery and portal vein, of which portal vein supply accounts for 75% to 80% and hepatic artery supply accounts for 20% to 25%. The blood supply of hepatocellular carcinoma is exactly the opposite, with more than 90% to 95% of the blood supply from hepatic artery and very little blood supply from portal vein. This brings convenience to the treatment. Through hepatic artery cannulation, drugs can directly enter liver cancer tissues to increase the local drug concentration and kill cancer cells. In addition, some embolic substances such as iodine oil, gelatin sponge and biocompatible embolic microspheres are applied to embolize the blood supply arteries of hepatocellular carcinoma to cut off its nutritional effect, and the tumor tissues will be necrosed, thus achieving the purpose of treatment. Interventional treatment for hepatocellular carcinoma is feasible for the following patients: (1) Primary or metastatic hepatocellular carcinoma that is considered inoperable for various reasons, or small hepatocellular carcinoma that the patient does not want to operate. (2) As a preparation before surgery, liver cancer can be shrunk through interventional treatment, which makes surgery easy to remove, and in addition, tumor spread and recurrence can be reduced after intervention. (3) Patients with incomplete resection of hepatocellular carcinoma, postoperative recurrence or failure of other methods of treatment. (4) For ruptured hepatocellular carcinoma lesion bleeding, it can stop the bleeding immediately and kill the lesion at the same time, and it is less risky than surgical operation. (5) No serious damage to liver or kidney function. (6) Patients without severe jaundice and ascites. (7) Patients with good general condition and no serious bleeding disorders.